Dopamine metabolism & DOPAL
Dopamine quinones, DOPAL toxicity and aldehyde dehydrogenase deficits driving selective nigral vulnerability.
State of the art
No update yet for Dopamine metabolism & DOPAL. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Exercise and smoking: health rivals revealing shared protective mechanisms in Parkinson’s?
Modulation of dopamine signalling and metabolism is described as a convergent mechanism shared by exercise and certain tobacco components, offering clues to how these disparate exposures may protect dopaminergic neurons in the substantia nigra. -
Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease
Demonstrates in a human surgical setting that non-dopaminergic striatal neurons can be reprogrammed via lentiviral delivery of TH, GCH1, and AADC to synthesise dopamine continuously from endogenous tyrosine, bypassing the degenerating nigrostriatal pathway — a proof-of-concept for continuous enzymatic dopamine replacement at the site of depletion. -
Region-specific cortico-striatal transcriptomic remodeling following early postnatal dopaminergic disturbance
A mouse study using early postnatal 6-OHDA (the same dopamine-depleting neurotoxin used in adult PD models) found 369 gene-expression changes in the prefrontal cortex and 493 in the striatum, with region-specific patterns: cortical changes reflected developmental and signalling programs, while striatal changes reflected locomotor regulation, extracellular matrix organisation, and amphetamine response. The results provide a gene-level map of how dopamine loss reshapes corticostriatal molecular programs — relevant to understanding why circuits fail in PD.